Armata Pharmaceuticals Gross Margin 2006-2021 | ARMP

Current and historical gross margin for Armata Pharmaceuticals (ARMP) over the last 10 years. The current gross profit margin for Armata Pharmaceuticals as of September 30, 2021 is %.
Armata Pharmaceuticals Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $0.00B $0.00B 100.00%
2021-06-30 $0.00B $0.00B 100.00%
2021-03-31 $0.00B $0.00B 100.00%
2017-12-31 $0.00B 0 nan%
2017-09-30 $0.00B 0 nan%
2017-06-30 $0.00B 0 nan%
2017-03-31 $0.00B 0 nan%
2016-12-31 $0.00B 0 nan%
2016-09-30 $0.00B 0 nan%
2016-06-30 $0.00B 0 nan%
2016-03-31 $0.00B 0 nan%
2015-12-31 $0.00B 0 nan%
2015-09-30 $0.00B 0 nan%
2015-06-30 $0.00B 0 nan%
2015-03-31 $0.00B 0 nan%
2014-12-31 $0.00B 0 nan%
2014-09-30 $0.00B 0 nan%
2014-06-30 $0.00B 0 nan%
2014-03-31 $0.00B 0 nan%
2013-12-31 $0.00B 0 nan%
2013-06-30 $0.00B $0.00B 100.00%
2013-03-31 $0.01B $0.01B 100.00%
2009-12-31 $0.01B $0.01B 100.00%
2009-09-30 $0.01B $0.01B 100.00%
2009-06-30 $0.01B $0.01B 100.00%
2009-03-31 $0.01B $0.01B 100.00%
2008-12-31 $0.01B $0.01B 100.00%
2008-09-30 $0.01B $0.01B 100.00%
2008-06-30 $0.01B $0.01B 100.00%
2008-03-31 $0.01B $0.01B 100.00%
2007-12-31 $0.01B $0.01B 100.00%
2007-09-30 $0.01B $0.01B 100.00%
2007-06-30 $0.01B $0.01B 100.00%
2007-03-31 $0.01B $0.01B 100.00%
2006-12-31 $0.01B $0.01B 100.00%
2006-09-30 $0.01B $0.01B 100.00%
2006-06-30 $0.01B $0.01B 100.00%
2006-03-31 $0.01B $0.01B 100.00%
2005-12-31 $0.01B $0.01B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.142B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88